Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -99.59% | -100.61% | -100.00% | +0.00% | -100.00% |
| Gross Profit Growth | -100.40% | -100.67% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | -496.59% | -1911.81% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -504.17% | -2202.07% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -447.98% | -893.62% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -445.16% | -883.48% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -456.67% | -904.09% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.00% | +1.75% | +26.30% | +31.04% | +37.07% |
| Weighted Average Shares Diluted Growth | -2.38% | -0.87% | +26.30% | +31.04% | +37.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -535.45% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -547.35% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -94.10% | -98.88% | -98.53% | -95.04% | -86.60% |
| Inventory Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -46.27% | -62.58% | -47.38% | -41.41% | +44.68% |
| Book Value per Share Growth | -53.57% | -62.64% | -50.84% | -50.97% | +23.45% |
| Debt Growth | -46.16% | -53.25% | -62.59% | +89.81% | +131.20% |
| R&D Expense Growth | -29.30% | -49.03% | -39.58% | +17.01% | -6.51% |
| SG&A Expenses Growth | -63.41% | -67.27% | -72.85% | -27.75% | -9.29% |